2026 Ebola Outbreak — DRC (Bundibugyo Virus)

The Democratic Republic of the Congo declared its 17th Ebola outbreak on May 15, 2026, caused by Bundibugyo virus — an established ebolavirus species, not a new one. It has since become the second-largest Ebola outbreak ever recorded, and the WHO declared a Public Health Emergency of International Concern on May 17, 2026.

Sources: CDC Ebola situation summary (September 14, 2026), WHO Disease Outbreak News 617 (September 10, 2026), CDC MMWR, DRC Ministry of Health. Data as of September 12, 2026 · Last reviewed: September 14, 2026.

Current Outbreak Status

This is a rapidly evolving situation and case counts change frequently. Always verify with the CDC Ebola situation summary and WHO Disease Outbreak News for the latest official numbers.

Active Outbreak

DRC — Bundibugyo Virus Disease (2026)

Declared May 15, 2026 (by DRC Ministry of Health) — the 17th Ebola outbreak in DRC
Causative species Bundibugyo virus (BDBV) — an established ebolavirus species, first identified in Uganda in 2007
Affected areas Six DRC provinces and 61 health zones per WHO (Ituri, North Kivu, South Kivu, Haut-Uélé, Tshopo, Bas-Uélé); CDC lists Sud-Ubangi rather than Bas-Uélé as the sixth — see note below. Uganda's linked outbreak (Kampala) has been declared over.
Vaccine available? No approved vaccine for Bundibugyo virus. Ervebo, the only licensed Ebola vaccine, is approved against Zaire ebolavirus, a different species; it is being given to health workers under a WHO research protocol because its effect on Bundibugyo virus is unknown.
Approved treatment? No approved treatment for Bundibugyo virus. Inmazeb and Ebanga are approved against Zaire ebolavirus; care relies on early supportive treatment.
WHO classification Public Health Emergency of International Concern (PHEIC) — declared May 17, 2026; reaffirmed by the second IHR Emergency Committee meeting on August 18, 2026

Sources: CDC — Ebola Outbreak: Current Situation, WHO Disease Outbreak News

Reported cases and deaths

  • DRC (as of September 12, 2026): 7,200 confirmed cases · 3,475 confirmed deaths (crude CFR ≈ 48%) · probable cases not included in DRC's official count; suspected cases temporarily excluded pending investigation
  • Uganda (as of September 13): 20 confirmed cases · 2 confirmed deaths · 1 probable case · 1 probable death (outbreak declared over)
  • France (as of September 13): 1 imported case · 0 deaths
  • Total: 7,221 confirmed cases · 3,477 confirmed deaths (plus 1 probable case and death)

Source: CDC — Ebola Outbreak: Current Situation · Data as of September 12–13, 2026, page dated September 14, 2026. Figures for this ongoing outbreak change frequently; check the linked source for the latest. Previous figure on this page: 4,053 confirmed cases and 1,850 deaths in DRC as of August 5, 2026 — an increase of 3,147 cases and 1,625 deaths in 38 days (our calculation).

WHO's count (Disease Outbreak News 617, data as of September 7, 2026): 6,757 confirmed cases and 3,267 deaths in DRC, crude CFR 48.3%, with at least 1,590 patients recovered; 6,778 confirmed cases and 3,269 deaths across all countries. CDC and WHO differ because they publish on different days from the same DRC Ministry of Health reports.

Risk to the United States: CDC assesses the risk to the general U.S. population as low (risk page updated September 8, 2026), and no cases from this outbreak have been reported on U.S. soil. Travelers who have been in DRC within 21 days — U.S. citizens included — cannot board commercial flights to the United States; travelers from Uganda or South Sudan are routed through Washington-Dulles, Atlanta or New York-JFK for entry screening (CDC order under 42 CFR 71.40). Two U.S. citizens infected while working in DRC were medically evacuated to Germany, in May and July 2026; both recovered (WHO DON 603, 613, 617).

Correction, September 14, 2026. This page previously said one U.S. aid worker had been evacuated to Germany; WHO had reported a second by July 17, 2026. Logged on our corrections page.

Check Current CDC Travel Notices →

Why This Outbreak Is the Second-Largest on Record

The species is familiar, but the trajectory is not. The 2026 outbreak has spread faster than any previous Ebola outbreak.

Scale and Speed

The only larger Ebola outbreak in history is the 2014–2016 West Africa epidemic (Zaire ebolavirus), which caused more than 28,600 cases and 11,300 deaths. The 2026 DRC outbreak is now the largest ever recorded in the DRC — surpassing the 2018–2020 Kivu outbreak — and, according to CDC and WHO, the second-largest anywhere.

It is also the fastest-growing on record. CDC reports the outbreak surpassed 1,000 confirmed cases within about 40 days of response activation; by comparison, the 2018 DRC outbreak took roughly 235 days to pass 1,000 cases.

The Growth Curve, From CDC's Own Data File

CDC's situation page carries a chart comparing the first six months of the 2014, 2018 and 2026 outbreaks. The chart is fed by a public data file (updated September 13, 2026; sources DRC INSP and WHO; cases by date reported), which gives the daily cumulative count. Read directly, it shows the 2026 outbreak crossing 1,000 reported cases on day 38 after its first reported case, 4,000 on day 84, and 7,000 on day 120; West Africa in 2014 reached 1,000 on day 119 and 4,000 on day 168, and the 2018 DRC outbreak had 741 cases at day 180. At day 122 — the latest point for 2026 — the counts were 7,200 (2026), 1,093 (2014) and 438 (2018). The full table is on the outbreak history page.

Weekly growth, from the same file (our calculation from consecutive seven-day differences): about 780 new confirmed cases in the week to day 70, then 627, 521, 612, 625, 504, 548 and 600 in the weeks to day 119. The outbreak has been adding roughly 500–630 confirmed cases a week since mid-July — steady, not accelerating, and not yet falling. WHO's reports attribute part of each fortnight's rise to expanded testing and reconciliation of earlier data, so the curve mixes transmission with detection; the two cannot be separated from the published counts.

WHO reportData as ofDRC confirmed casesDeathsCrude CFRAlso reported
DON 603May 2185 (both countries)10746 suspected cases, 176 suspected deaths
DON 606June 65159117.7%Africa CDC–WHO plan launched, US$518M ask
DON 608June 1789623225.9%
DON 612July 11,46045231.0%36 health zones; 102 health-worker cases; French case notified June 24
DON 613July 152,12482839.0%Second U.S. citizen evacuated to Germany July 13
DON 614July 303,6051,58744%49 health zones; largest ever in DRC; Uganda declared over July 28
DON 615August 124,6652,18446.8%54 zones, 6 provinces (Bas-Uélé added); record week: 579 cases
DON 616August 265,7942,78648.1%60 zones; PHEIC reaffirmed Aug 18; Ervebo vaccination began Aug 27
DON 617September 76,7573,26748.3%61 zones; 24,719 contacts under follow-up; 2,007 vaccinated; PARTNERS >300 enrolled
Source: WHO Disease Outbreak News 603–617, May 22 – September 10, 2026, each report's own "as of" date. Crude CFR = deaths ÷ confirmed cases as WHO states it (DON 606–613 values are our calculation from WHO's counts). The rising ratio through July reflects deaths lagging cases in a growing outbreak as much as any change in the disease.

Where the Cases Are

In DRC, transmission spans six provinces and 61 health zones as of September 7, 2026 (WHO DON 617): Ituri (28 of its 36 health zones affected; 5,406 cumulative cases, 80% of the total), North Kivu (16 of 34 zones; 1,066 cases, and the outbreak's highest provincial CFR at 65.4%, under investigation), Tshopo (7 of 23), Haut-Uélé (6 of 13), Bas-Uélé (3 of 11; first case with onset August 4), and South Kivu (1 of 34; no case since May 29). The newest health zone is Kayna, North Kivu. Fifty-one zones in five provinces reported a case in the 21 days to September 7.

Where CDC and WHO differ. CDC's situation summary (September 14) lists the six affected provinces as Haut-Uélé, Ituri, North Kivu, South Kivu, Sud-Ubangi and Tshopo. WHO's report of the same week lists Bas-Uélé in place of Sud-Ubangi, names its three affected zones (Buta, Ganga, Viadana), and dates its first case. Sud-Ubangi lies in the far west of the country; Bas-Uélé borders Haut-Uélé. We follow WHO's list here because it is the more specific, and we note that the two agencies' pages disagree. We do not know why.

In Uganda, all cases were in the capital, Kampala, and every one traced to DRC: 14 of the 20 confirmed patients were infected in DRC and crossed into Uganda while symptomatic; four Ugandan health workers were infected during the attempted resuscitation of a probable case who was embalmed before testing, and a driver through contact with a body (CDC MMWR 2026;75(35):551). Uganda's last confirmed case was June 21. The Ministry of Health declared the outbreak over on July 28 per WHO (DON 614); CDC's MMWR gives August 26; the 42-day enhanced monitoring period for the last imported patient ended August 27 (DON 616). Of the 20 confirmed Ugandan cases, 2 died — a fatality rate of 10% for the same virus that has killed 48% of confirmed cases in DRC.

Health Workers

Health workers have been hit hard. WHO's counts for DRC: 102 confirmed infections and 25 deaths by July 1; 119 and 36 by July 15; 151 and 44 by July 30; at least 155 infections and 45 deaths by August 9, 2026 (CFR 29%), driven by limited protective equipment, security concerns, and infection-control gaps in a conflict-affected region. WHO's August 28 and September 10 reports did not restate the figure, so no more recent count exists (DON 612–617). The healthcare worker page tabulates the series.

Is the Response Working? CDC's Indicators

CDC tracks the DRC response against operational targets and published the status as of August 21, 2026 (CDC MMWR 2026;75(35):554): 10.6 contacts identified per case against a target of 20 or more; 15–20% of new cases previously known as contacts against a target above 90%; 72% of validated alerts tested against 90%; test positivity 24% against a target of zero; 59% of confirmed deaths occurring outside a treatment unit against a target of zero; and 49% of affected health zones with a safe-burial team against 100%. CDC's conclusion: the indicators "indicate uncontrolled expansion of the outbreak." WHO's risk assessment of August 14 rates the risk as very high in DRC, high for countries sharing a land border, and low for the rest of Africa and globally (DON 617). The prevention page gives the full indicator table.

What CDC Projected in June — and What Happened

On June 11, 2026 CDC published scenario projections (Mooring et al., MMWR): with only 20% of patients isolated and no other interventions, a 65% likelihood of more than 20,000 cases within three months; with 70% isolation, a one-in-twenty chance of 10,000. Three months later, DRC's confirmed count stood at roughly 6,600 (6,342 at day 112 and 6,942 at day 119 of CDC's data file, i.e. September 2–9) — below both thresholds, though the operational review above shows isolation and tracing targets still unmet. The model also placed the spillover event in mid-to-late February 2026; the earliest reconstructed symptom onset is April 24, with laboratory detection 20 days later on May 14 (Elvis Akem et al., PLOS Global Public Health 2026).

Why the Species Matters for Vaccines and Treatment

Bundibugyo virus is well-characterized — but the approved Ebola countermeasures were built for a different species.

An Established Species, Not a Novel Variant

The genus Orthoebolavirus contains six recognized species: Zaire, Sudan, Bundibugyo, Reston, Taï Forest, and Bombali. Three — Zaire, Sudan, and Bundibugyo — have caused large human outbreaks. Bundibugyo virus was first identified during a 2007 outbreak in Bundibugyo District, Uganda (Towner et al., PLoS Pathogens 2008), and caused a smaller outbreak in DRC in 2012. Historically, Bundibugyo outbreaks have had case fatality rates in the range of about 25–50% — the exact figures depend on the source: CDC's history page gives 32% (2007) and 55% (2012); WHO gives 30% and 50%; a 2024 meta-analysis pooled them at 32.8% (95% CI 25.8–40.2; Izudi et al.). The 2026 crude CFR of 48% sits above that historical interval; the symptoms page sets out the three candidate explanations — late or no care, undetected mild cases, or a real difference — and the evidence for each.

The Approved Countermeasures Target Zaire, Not Bundibugyo

This distinction is the single most important thing to understand about the 2026 response:

  • Vaccines: Ervebo (rVSV-ZEBOV, Merck) is FDA-approved for "the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older" and, per CDC, "does not provide protection against other species of orthoebolaviruses." It is the only licensed Ebola vaccine: the two-dose Zabdeno/Mvabea regimen (Janssen) had its EU marketing authorisations withdrawn at the company's request on May 1, 2026 and was never marketed (EMA).
  • Treatments: Inmazeb (atoltivimab/maftivimab/odesivimab) and Ebanga (ansuvimab) are monoclonal antibodies approved against Zaire ebolavirus. Both FDA labels carry the same limitation: efficacy "has not been established for other species of the Orthoebolavirus and Orthomarburgvirus genera."
  • What is being used: Early, aggressive supportive care — fluids, electrolytes, and treatment of complications — remains the backbone of care and improves survival. WHO's PARTNERS therapeutics trial began enrolling on July 2, 2026 and had more than 300 patients at five Ituri facilities by September 10 (DON 617); no result has been published. In Uganda all 18 treatment-unit patients received remdesivir under compassionate use, and 18 of 20 confirmed cases survived — an uncontrolled series whose authors say a trial "might be warranted" (CDC MMWR 2026;75(35):551).

Ervebo Under a Research Protocol — the WHO Decisions in Order

On August 7, 2026 WHO's Technical Advisory Group on candidate vaccine prioritisation recommended Ervebo be prioritised for a randomised trial in the outbreak. On August 19, WHO's SAGE concluded that "available evidence remains insufficient to support the programmatic use of Ervebo for the prevention of BVD, and that its efficacy against BVD in humans remains unknown," recommending use only within a research protocol. On August 27 vaccination of health workers began in Kisangani, Tshopo. By September 6, 2026, 2,007 health and frontline workers had been vaccinated across six health zones in Tshopo, Bas-Uélé and Ituri (WHO DON 616, 617). Whether it protects them is the question the protocol exists to answer.

The only Bundibugyo-specific vaccine in human trials on ClinicalTrials.gov (checked September 14, 2026) is Moderna's mRNA-1469 — a Phase 1 placebo-controlled study in 84 healthy adults at three Canadian sites, begun July 31, 2026, with an estimated completion date of September 30, 2027 (NCT07737717). Phase 1 measures safety and immune response, not protection. There are still no proven vaccines or treatments for the Bundibugyo species.

Clarification, September 14, 2026. This page previously described a Bundibugyo-specific candidate vaccine as being in "preclinical testing" from July 2026 in the UK and Canada under the WHO R&D Blueprint. We could not verify that statement against a primary source; the registered study above is a Phase 1 human trial in Canada. Logged on our corrections page.

Compared to what? For Ebola's exposure, hospitalisation and fatality alongside 14 other viruses, see the Virus Risk Perspective and this site's Ebola risk perspective.

For healthcare workers in or returning from affected regions: Follow your institution's Ebola preparedness protocol and report any exposure to occupational health immediately. Full Ebola PPE is required when caring for suspected or confirmed cases. See healthcare worker guidance →

Frequently Asked Questions

What virus is causing the 2026 Ebola outbreak in DRC?

The 2026 outbreak is caused by Bundibugyo virus (BDBV), one of the established ebolavirus species — not a new or unknown virus. Bundibugyo virus was first identified in western Uganda in 2007 and caused earlier, smaller outbreaks in Uganda (2007) and DRC (2012). What is unusual in 2026 is the scale and speed — it is the second-largest Ebola outbreak ever recorded — not the species itself.

How many cases and deaths are there in the 2026 Ebola outbreak?

As of September 12, 2026, CDC reported 7,200 confirmed cases and 3,475 confirmed deaths in DRC — a crude case fatality rate of about 48%. Including Uganda (20 confirmed cases and 2 deaths, plus one probable case and death) and a single imported case in France, the totals were 7,221 confirmed cases and 3,477 confirmed deaths. WHO's count as of September 7 was 6,757 cases and 3,267 deaths in DRC (DON 617). Case counts change frequently; check the CDC situation summary for the latest.

Is there an approved vaccine or treatment for the 2026 outbreak?

No. There is no approved vaccine or specific treatment for Bundibugyo virus. The one licensed vaccine (Ervebo) and the antibody treatments (Inmazeb and Ebanga) were approved against Zaire ebolavirus, a different species; the FDA labels say efficacy "has not been established for other species." WHO's SAGE concluded on August 19, 2026 that Ervebo's efficacy against Bundibugyo virus remains unknown and recommended use only within a research protocol, under which 2,007 health workers had been vaccinated by September 6. WHO's PARTNERS therapeutics trial has enrolled more than 300 patients with no published result. Care relies on early supportive treatment. See the full treatment & vaccines page →

What is a PHEIC and when was it declared?

A Public Health Emergency of International Concern (PHEIC) is the WHO's highest alert level — declared when an event poses a public health risk to other countries through international spread and may require a coordinated response. The WHO Director-General declared the 2026 DRC Ebola outbreak a PHEIC on May 17, 2026, two days after DRC declared the outbreak. The IHR Emergency Committee met again on August 18, 2026 and the Director-General agreed the outbreak remains a PHEIC, issuing updated temporary recommendations on August 24 (WHO DON 616, 617).

Is the 2026 Ebola outbreak a risk to the United States?

CDC assesses the risk to the general U.S. population as low (updated September 8, 2026), and no cases from this outbreak have been reported in the United States. Travelers who have been in DRC within 21 days cannot board commercial flights to the U.S.; travelers from Uganda or South Sudan are routed through designated airports for screening. Two U.S. citizens infected while working in DRC were evacuated to Germany, in May and July 2026, and both recovered (WHO). See travel-risk guidance → · Ebola in the U.S. →

What should I do if I recently traveled to eastern DRC?

If you were in Ituri, North Kivu, Haut-Uélé, Tshopo, Bas-Uélé or South Kivu provinces in the past 21 days, monitor your health daily for fever (≥38°C / 100.4°F), severe headache, muscle pain, vomiting, diarrhea, or unexplained bleeding. If symptoms develop, isolate immediately and call your healthcare provider or the CDC Emergency Operations Center at (770) 488-7100 before going anywhere. Do not self-transport to an ER — call first so infection control can be prepared.

Sources & References

  1. Centers for Disease Control and Prevention. Ebola Outbreak: Current Situation. cdc.gov/ebola/situation-summary
  2. World Health Organization. Disease Outbreak News — Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo. who.int/emergencies/disease-outbreak-news
  3. World Health Organization. Ebola disease — Key Facts. who.int/news-room/fact-sheets/detail/ebola-disease
  4. Centers for Disease Control and Prevention. Travel Health Notices. wwwnc.cdc.gov/travel/notices
  5. Centers for Disease Control and Prevention, Center for Forecasting and Outbreak Analytics. Risk to the U.S. Population from the 2026 Ebola Disease Outbreak Caused by Bundibugyo Virus. Updated September 8, 2026. cdc.gov/cfa-qualitative-assessments
  6. Mooring EQ, et al. Modeled Scenario Projections for the Ebola Disease Outbreak Caused by Bundibugyo Virus, 2026. MMWR 2026;75(22):285–289. doi:10.15585/mmwr.mm7522e1
  7. Kabasele D, et al. Notes from the Field: Characteristics and Monitoring of the 2026 Outbreak — DRC, August 2026. MMWR 2026;75(35):554–556. doi:10.15585/mmwr.mm7535e1
  8. Mutegeki M, et al. Notes from the Field: Clinical Characteristics of Patients — Uganda, 2026. MMWR 2026;75(35):551–553. doi:10.15585/mmwr.mm7535a2
  9. Elvis Akem T, et al. Operational epidemiology of the early phase of the 2026 Bundibugyo virus disease outbreak. PLOS Glob Public Health 2026;6(8):e0006680. doi:10.1371/journal.pgph.0006680
  10. Towner JS, et al. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008;4(11):e1000212. doi:10.1371/journal.ppat.1000212
  11. Izudi J, Bajunirwe F. Case fatality rate for Ebola disease, 1976–2022: A meta-analysis of global data. J Infect Public Health 2024;17(1):25–34. doi:10.1016/j.jiph.2023.10.020
  12. U.S. Food and Drug Administration. INMAZEB and EBANGA prescribing information (openFDA); ERVEBO (content current April 21, 2026). fda.gov/vaccines-blood-biologics/ervebo
  13. European Medicines Agency. Zabdeno and Mvabea — marketing authorisations withdrawn May 1, 2026. ema.europa.eu/…/zabdeno
  14. ClinicalTrials.gov. NCT07737717 — mRNA-1469 Bundibugyo virus vaccine, Phase 1. clinicaltrials.gov/study/NCT07737717